New drug targets Cancer's genetic weakness
NCT ID NCT06390865
Summary
This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced cancers that have stopped responding to other treatments. The drug is specifically for patients whose tumors have certain genetic changes called TSC1 or TSC2 mutations. The goal is to see if blocking specific enzymes can stop or slow cancer growth in these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.